Therakind Presents a Poster at the 3rd Annual Inhaled & Nasal Biologics Forum 2024
The Impact of the Filling Process on the Performance of a Spray-dried Formulation from the DriDose® Nasal Powder Delivery Device
London, England – September 2024 – Therakind Limited (“Therakind”), a specialty pharmaceutical company focused on developing and delivering niche medicines, will present a poster at the Inhaled & Nasal Biologics Forum in Cambridge, 26-27 September 2024 – a forum for academic and industry experts working with respiratory drug delivery.
The Poster, titled “The Impact of the Filling Process on the Performance of a Spray Dried Formulation from the DriDose® Nasal Powder Delivery Device” evaluates efficient dry powder filling into the DriDose® Multi-dose Cartridge device. This poster was produced following a study performed in collaboration with 3P and another company (undisclosed).
Dr. Julie-Ann Penton, Therakind's Director of Pharmaceutical Development, said: “We are excited to share the outcome of a DriDose filling study performed using a novel candidate formulation in collaboration with 3P innovation, specialists in crafting pharmaceutical filling solutions. We were delighted to demonstrate consistent powder filling into DriDose®cartridges as part of our programme to develop the filling process for our novel nasal devices.”
Therakind has a portfolio of dry powder intranasal devices and expertise in formulation development and regulatory strategy. More specifically, Therakind’s novel DriDose® Multi-dose Cartridge device is reusable and does not require coordinated breathing. The DriDose® innovative dry powder nasal delivery device range is designed to incorporate various types of pharmaceutical candidates. The technology includes both single-use and reusable versions, each capable of being modified to accommodate different powder-loading capacities. The reusable device is designed to reduce plastic waste associated with single-use devices and injections. The DriDose® device aims to simplify drug delivery and provide an alternative to nasal sprays, nebulizers, tablets, and injections. DriDose® technology has been validated in a clinical trial and tested with a range of molecules in both in vivo and in vitro settings.
Join us at https://www.intertek.com/pharmaceutical/events/inhaled-nasal-biologics-dna-forum/
if you would like to learn more about Therakind’s DriDose® technology, and contact us at: bd@therakind.com
For more information, please contact:
Therakind Ltd
Dr Susan Conroy, Chief Executive Officer
Tel: ++44 (0) 208 346 603
Email: info@therakind.com
Website: www.therakind.com
About Therakind Limited
Therakind is a specialty pharmaceutical company with a proprietary and partnered pipeline focused on improving medicine adherence through more patient-friendly dosing options. We have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to incorporate the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. To date, we have developed and obtained marketing authorisations for three products and our intranasal device for the delivery of a dry powder drug formulation, DriDose®, is available for co-development.
To find out more, please visit www.therakind.com